Research programme: small molecule therapeutics - Recursion Pharmaceuticals
Alternative Names: Antifibrotic therapeutics - Recursion Pharmaceuticals; Target epsilon - Recursion PharmaceuticalsLatest Information Update: 05 Mar 2024
At a glance
- Originator Bayer
- Developer Recursion Pharmaceuticals
- Class Antifibrotics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Fibrosis